for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eli Lilly And Co

LLY.N

Latest Trade

114.35USD

Change

1.63(+1.45%)

Volume

972,620

Today's Range

112.44

 - 

115.11

52 Week Range

104.19

 - 

132.12

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
112.72
Open
112.87
Volume
972,620
3M AVG Volume
78.04
Today's High
115.11
Today's Low
112.44
52 Week High
132.12
52 Week Low
104.19
Shares Out (MIL)
965.43
Market Cap (MIL)
107,278.90
Forward P/E
19.55
Dividend (Yield %)
2.32

Next Event

Q3 2019 Eli Lilly and Co Earnings Release

Latest Developments

More

Eli Lilly Says To Submit New Drug Application For Selpercatinib By Year-End

Eli Lilly Says U.S. FDA Approved Taltz Injection 80 Mg/Ml For Treatment Of Adults With Active Ankylosing Spondylitis

Lilly Announces Top-Line Phase 3 Results For Oral JAK Inhibitor Baricitinib, In Combination With Topical Corticosteroids In Adult Patients With Moderate To Severe Atopic Dermatitis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eli Lilly And Co

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry

Biotechnology & Drugs

Contact Info

Lilly Corporate Ctr, Drop Code 1112

+1.317.2762000

https://www.lilly.com/

Executive Leadership

David A. Ricks

Chairman of the Board, President, Chief Executive Officer

Joshua L. Smiley

Chief Financial Officer, Senior Vice President

Michael J. Harrington

Executive Vice President, General Counsel

Aarti S. Shah

Senior Vice President - Chief Information and Digital Officer

Daniel M. Skovronsky

Senior Vice President, Chief Scientific Officer

Key Stats

2.53 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

21.2K

2017

22.9K

2018

24.6K

2019(E)

22.3K
EPS (USD)

2016

3.520

2017

4.280

2018

5.550

2019(E)

5.685
Price To Earnings (TTM)
25.26
Price To Sales (TTM)
4.62
Price To Book (MRQ)
38.60
Price To Cash Flow (TTM)
18.81
Total Debt To Equity (MRQ)
567.75
LT Debt To Equity (MRQ)
493.35
Return on Investment (TTM)
15.50
Return on Equity (TTM)
10.71

Latest News

Eli Lilly wins Fed Circuit decision fending off generic Alimta

Eli Lilly and Company won a federal appeals court decision on Friday that protects its chemotherapy drug Alimta from generic competition from Pfizer Inc and Dr Reddy's Laboratories Ltd.

Study shows Apple devices in combo with apps could identify dementia

Drugmaker Eli Lilly said on Thursday early results from a study suggest that Apple Inc devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer's disease dementia and those without symptoms.

Study shows Apple devices in combo with apps could identify dementia

Drugmaker Eli Lilly said initial results from a study suggest that Apple Inc devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer's disease dementia and those without symptoms.

Newer drugs help Eli Lilly top Wall Street quarterly profit estimate

Eli Lilly and Co <LLY.N> reported a second-quarter profit that topped Wall Street estimates and raised its 2019 earnings forecast on Tuesday, as higher demand for newer drugs offset increased discounts for the U.S. Medicare program and sales declines of medicines that lost...

Eli Lilly tops revenue estimates on diabetes drug boost

Eli Lilly and Co edged past Wall Street estimates for quarterly revenue on Tuesday, as higher sales of its top-selling diabetes drug, Trulicity, helped offset the impact of generic competition on its erectile dysfunction drug, Cialis.

Eli Lilly's hypoglycemia treatment wins FDA approval

The U.S. Food and Drug Administration approved Eli Lilly and Co's treatment for severe hypoglycemia, the health regulator said on Wednesday.

UPDATE 1-Eli Lilly's bio-medicines head to leave next month

Drugmaker Eli Lilly and Co said on Thursday Christi Shaw, president of its bio-medicines business, would leave the company at the end of next month.

Eli Lilly's bio-medicines head to leave next month

Drugmaker Eli Lilly and Co said on Thursday Christi Shaw, president of its bio-medicines business, would leave the company at the end of next month.

U.S. judge strikes down Trump administration rule requiring drug prices in TV ads

A federal judge on Monday dealt a blow to the Trump administration by striking down a new rule that would have forced pharmaceutical companies to include the wholesale prices of their drugs in television advertising.

Eli Lilly misses estimates for top-selling diabetes drug Trulicity, shares slip

Eli Lilly and Co on Tuesday reported lower-than-expected first-quarter sales for its top-selling diabetes drug Trulicity, and the U.S. drugmaker said the need to offer rebates and discounts were taking a toll and likely to weigh on revenue growth for the year.

Eli Lilly quarterly profit more than triples on Elanco gain

Eli Lilly and Co's first-quarter profit more than tripled, as the U.S. drugmaker recorded a $3.7 billion gain from its spin-off of animal health unit Elanco.

Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study

A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday.

Astellas, Eli Lilly must face lawsuit alleging underpaid Medicaid rebates

Astellas Pharma and Eli Lilly and Co must face a whistleblower lawsuit accusing them of knowingly underpaying rebates they owed to state Medicaid programs, a federal judge has ruled.

Eli Lilly seeks to quell drug price anger with cheaper insulin

Drugmaker Eli Lilly announced plans on Monday to sell a half-price version of its popular insulin injection Humalog, as it fends off criticism about rising drug prices in the United States.

Lilly to introduce lower-priced insulin injection

U.S. drugmaker Eli Lilly and Co said on Monday it would introduce a generic version of its Humalog insulin injection at a 50 percent lower list price than previous versions.

Pfizer-Lilly drug shown to help reduce back pain in late-stage trial

A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday.

Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology.

Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo

German drugmaker Bayer acquired all rights it does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly's Loxo Oncology.

Eli Lilly backs U.S. proposal on drug rebates to lower costs

Eli Lilly and Co on Wednesday embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen, saying it could lower the cost of insulin and other prescription drugs for patients.

Eli Lilly quarterly sales beat expectations

Eli Lilly and Co posted better-than-expected fourth-quarter revenue on Wednesday, helped by higher sales of its newer drugs such as diabetes treatment Trulicity and psoriatic arthritis medication Taltz.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up